KJKautilya Kumar Jena

Kautilya Kumar Jena

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kautilya Kumar Jena has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines

    by Kautilya K Jena, Pengxiang Qu, Lauren Baracco, Shahab Saghaei, Zahra Allahyari, Daniel Boehmer, Moriah Mitchell, Carly A Dillen, Hai-Yun Li, Enqi Liu, et al.

    The activation of pattern recognition receptors (PRRs) orchestrates inflammation and regulates adaptive immunity. To test whether tuning inflammation through PRR stimulation enhanced the efficacy of mRNA vaccines, we combined an mRNA-based vaccine generated against the ancestral spike protein of SARS-CoV-2 with mannadjuvant, a formulation of fungal mannan and aluminum hydroxide targeting the PRR dectin-2. In mice and non-human primates, mannadjuvant increased the magnitude and durability of the response elicited by the mRNA-based vaccine, and it also led to the induction of neutralizing antibodies directed against variants of concern with a high escape capacity, overcoming antigenic imprinting. Mechanistically, prolonged type I interferon (IFN) production and potentiated interleukin-1 (IL-1) signaling locally within the draining lymph node in mice or in human cells were necessary and sufficient to exert the effect of mannadjuvant. Our data indicate that antifungal PRRs can be harnessed to create more potent and durable mRNA-based vaccines.


  • Open Access

    Programmed cell revival from imminent cell death enhances tissue repair and regeneration

    by Kollori Dhar, Kautilya Kumar Jena, Subhash Mehto, Rinku Sahu, Krushna C Murmu, Atharva Anand Mahajan, Sibaram Behera, Ravi Kiran Putchala, Reuben Jacob Mathew, Ramyasingh Bal, et al.

    Cell recovery from near-death states is a critical yet poorly understood aspect of cell biology. Here, we describe a tightly-regulated programmed cell revival process after exposure of cells to cell death-inducing lysosomotropic agents, such as L-leucyl-L-leucine methyl ester (LLOMe). In the initial stage of cell recovery, we observe increased chromatin accessibility and upregulation of genes and pathways associated with embryonic development, regeneration, stemness, and inflammation. Subsequently, vital pathways governing metabolism, organelle biogenesis, membrane trafficking, transport, and cytoskeleton remodeling are activated, resulting in the complete renewal of cells. Consistent with the links of this transcriptional profile to tissue repair and regeneration, we found LLOMe to enhance the healing of skin wounds and corneal alkali burns in mice, promote hematopoietic progenitor/stem cell production in Drosophila melanogaster , induce tadpole tail regeneration in frogs, and mediate axon regeneration in Caenorhabditis elegans . Using both genetic and pharmacological approaches, we show NF-ĸB signaling to be critical for both cell revival and regeneration. This study characterizes cell revival from near-death conditions as a programmed cell-intrinsic mechanism, which could be harnessed for therapeutic applications in regenerative medicine.


  • Open Access

    Data from RNA-Binding RING E3-Ligase DZIP3/hRUL138 Stabilizes Cyclin D1 to Drive Cell-Cycle and Cancer Progression

    by Srinivasa P. Kolapalli, Rinku Sahu, Nishant R. Chauhan, Kautilya K. Jena, Subhash Mehto, Saroj K. Das, Ashish Jain, Manaswini Rout, Rupesh Dash, Rajeeb K. Swain, et al.

    DZIP3/hRUL138 is a poorly characterized RNA-binding RING E3-ubiquitin ligase with functions in embryonic development. Here we demonstrate that DZIP3 is a crucial driver of cancer cell growth, migration, and invasion. In mice and zebrafish cancer models, DZIP3 promoted tumor growth and metastasis. In line with these results, DZIP3 was frequently overexpressed in several cancer types. Depletion of DZIP3 from cells resulted in reduced expression of Cyclin D1 and a subsequent G1 arrest and defect in cell growth. Mechanistically, DZIP3 utilized its two different domains to interact and stabilize Cyclin D1 both at mRNA and protein levels. Using an RNA-binding lysine-rich region, DZIP3 interacted with the AU-rich region in 3′ untranslated region of Cyclin D1 mRNA and stabilized it. Using a RING E3-ligase domain, DZIP3 interacted and increased K63-linked ubiquitination of Cyclin D1 protein to stabilize it. Remarkably, DZIP3 interacted with, ubiquitinated, and stabilized Cyclin D1 predominantly in the G1 phase of the cell cycle, where it is needed for cell-cycle progression. In agreement with this, a strong positive correlation of mRNA expression between DZIP3 and Cyclin D1 in different cancer types was observed. Additionally, DZIP3 regulated several cell cycle proteins by modulating the Cyclin D1–E2F axes. Taken together, this study demonstrates for the first time that DZIP3 uses a unique two-pronged mechanism in its stabilization of Cyclin D1 to drive cell-cycle and cancer progression.Significance:These findings show that DZIP3 is a novel driver of cell-cycle and cancer progression via its control of Cyclin D1 mRNA and protein stability in a cell-cycle phase-dependent manner.

  • Open Access

    Supplementary Data from RNA-Binding RING E3-Ligase DZIP3/hRUL138 Stabilizes Cyclin D1 to Drive Cell-Cycle and Cancer Progression

    by Srinivasa P. Kolapalli, Rinku Sahu, Nishant R. Chauhan, Kautilya K. Jena, Subhash Mehto, Saroj K. Das, Ashish Jain, Manaswini Rout, Rupesh Dash, Rajeeb K. Swain, et al.

    Supplementary Figures 1-6 and Methods. Supplementary Fig. S1: DZIP3 controls growth, migration, and invasion of cancer cells. Supplementary Fig. S2: DZIP3 promotes tumor growth and metastasis in Zebrafi¬sh model. Supplementary Fig. S3: DZIP3 controls cell cycle progression. Supplementary Fig. S4: DZIP3 interacts with Cyclin D1 mRNA and stabilizes it. Supplementary Fig. S5: DZIP3 interacts, co-localizes, and stabilizes Cyclin D1 protein. Supplementary Fig. S6: DZIP3 controls Cyclin D1-E2F target genes.

  • Open Access

    Supplementary Data from RNA-Binding RING E3-Ligase DZIP3/hRUL138 Stabilizes Cyclin D1 to Drive Cell-Cycle and Cancer Progression

    by Srinivasa P. Kolapalli, Rinku Sahu, Nishant R. Chauhan, Kautilya K. Jena, Subhash Mehto, Saroj K. Das, Ashish Jain, Manaswini Rout, Rupesh Dash, Rajeeb K. Swain, et al.

    Supplementary Figures 1-6 and Methods. Supplementary Fig. S1: DZIP3 controls growth, migration, and invasion of cancer cells. Supplementary Fig. S2: DZIP3 promotes tumor growth and metastasis in Zebrafi¬sh model. Supplementary Fig. S3: DZIP3 controls cell cycle progression. Supplementary Fig. S4: DZIP3 interacts with Cyclin D1 mRNA and stabilizes it. Supplementary Fig. S5: DZIP3 interacts, co-localizes, and stabilizes Cyclin D1 protein. Supplementary Fig. S6: DZIP3 controls Cyclin D1-E2F target genes.

  • Open Access

    Data from RNA-Binding RING E3-Ligase DZIP3/hRUL138 Stabilizes Cyclin D1 to Drive Cell-Cycle and Cancer Progression

    by Srinivasa P. Kolapalli, Rinku Sahu, Nishant R. Chauhan, Kautilya K. Jena, Subhash Mehto, Saroj K. Das, Ashish Jain, Manaswini Rout, Rupesh Dash, Rajeeb K. Swain, et al.

    DZIP3/hRUL138 is a poorly characterized RNA-binding RING E3-ubiquitin ligase with functions in embryonic development. Here we demonstrate that DZIP3 is a crucial driver of cancer cell growth, migration, and invasion. In mice and zebrafish cancer models, DZIP3 promoted tumor growth and metastasis. In line with these results, DZIP3 was frequently overexpressed in several cancer types. Depletion of DZIP3 from cells resulted in reduced expression of Cyclin D1 and a subsequent G1 arrest and defect in cell growth. Mechanistically, DZIP3 utilized its two different domains to interact and stabilize Cyclin D1 both at mRNA and protein levels. Using an RNA-binding lysine-rich region, DZIP3 interacted with the AU-rich region in 3′ untranslated region of Cyclin D1 mRNA and stabilized it. Using a RING E3-ligase domain, DZIP3 interacted and increased K63-linked ubiquitination of Cyclin D1 protein to stabilize it. Remarkably, DZIP3 interacted with, ubiquitinated, and stabilized Cyclin D1 predominantly in the G1 phase of the cell cycle, where it is needed for cell-cycle progression. In agreement with this, a strong positive correlation of mRNA expression between DZIP3 and Cyclin D1 in different cancer types was observed. Additionally, DZIP3 regulated several cell cycle proteins by modulating the Cyclin D1–E2F axes. Taken together, this study demonstrates for the first time that DZIP3 uses a unique two-pronged mechanism in its stabilization of Cyclin D1 to drive cell-cycle and cancer progression.Significance:These findings show that DZIP3 is a novel driver of cell-cycle and cancer progression via its control of Cyclin D1 mRNA and protein stability in a cell-cycle phase-dependent manner.

  • Open Access

    Selective autophagy of RIPosomes maintains innate immune homeostasis during bacterial infection

    by Subhash Mehto, Kautilya Kumar Jena, Rina Yadav, Swatismita Priyadarsini, Pallavi Samal, Sivaram Krishna, Kollori Dhar, Ashish Jain, Nishant Ranjan Chauhan, Krushna C Murmu, et al.

    The NOD1/2‐RIPK2 is a key cytosolic signaling complex that activates NF‐κB pro‐inflammatory response against invading pathogens. However, uncontrolled NF‐κB signaling can cause tissue damage leading to chronic diseases. The mechanisms by which the NODs‐RIPK2‐NF‐κB innate immune axis is activated and resolved remain poorly understood. Here, we demonstrate that bacterial infection induces the formation of endogenous RIPK2 oligomers (RIPosomes) that are self‐assembling entities that coat the bacteria to induce NF‐κB response. Next, we show that autophagy proteins IRGM and p62/SQSTM1 physically interact with NOD1/2, RIPK2 and RIPosomes to promote their selective autophagy and limit NF‐κB activation. IRGM suppresses RIPK2‐dependent pro‐inflammatory programs induced by Shigella and Salmonella. Consistently, the therapeutic inhibition of RIPK2 ameliorates Shigella infection‐ and DSS‐induced gut inflammation in Irgm1 KO mice. This study identifies a unique mechanism where the innate immune proteins and autophagy machinery are recruited together to the bacteria for defense as well as for maintaining immune homeostasis.


  • Open Access

    SMARCD1 negatively regulates myeloid differentiation of leukemic cells via epigenetic mechanisms

    by Subha Saha, Priyanka Samal, Swati Madhulika, Krushna Chandra Murmu, Sohini Chakraborty, Jhinuk Basu, Subhabrata Barik, Kautilya Kumar Jena, Asima Das, Santosh Chauhan, et al.

    Subha Saha, Priyanka Samal, Swati Madhulika, Krushna Chandra Murmu, Sohini Chakraborty, Jhinuk Basu, Subhabrata Barik, Kautilya Kumar Jena, Asima Das, Dr, Santo


  • Open Access

    RNA-Binding RING E3-Ligase DZIP3/hRUL138 Stabilizes Cyclin D1 to Drive Cell-Cycle and Cancer Progression

    by Srinivasa P. Kolapalli, Rinku Sahu, Nishant R. Chauhan, Kautilya K. Jena, Subhash Mehto, Saroj K. Das, Ashish Jain, Manaswini Rout, Rupesh Dash, Rajeeb K. Swain, et al.

    DZIP3/hRUL138 is a poorly characterized RNA-binding RING E3-ubiquitin ligase with functions in embryonic development. Here we demonstrate that DZIP3 is a crucial driver of cancer cell growth, migration, and invasion. In mice and zebrafish cancer models, DZIP3 promoted tumor growth and metastasis. In line with these results, DZIP3 was frequently overexpressed in several cancer types. Depletion of DZIP3 from cells resulted in reduced expression of Cyclin D1 and a subsequent G1 arrest and defect in cell growth. Mechanistically, DZIP3 utilized its two different domains to interact and stabilize Cyclin D1 both at mRNA and protein levels. Using an RNA-binding lysine-rich region, DZIP3 interacted with the AU-rich region in 3′ untranslated region of Cyclin D1 mRNA and stabilized it. Using a RING E3-ligase domain, DZIP3 interacted and increased K63-linked ubiquitination of Cyclin D1 protein to stabilize it. Remarkably, DZIP3 interacted with, ubiquitinated, and stabilized Cyclin D1 predominantly in the G1 phase of the cell cycle, where it is needed for cell-cycle progression. In agreement with this, a strong positive correlation of mRNA expression between DZIP3 and Cyclin D1 in different cancer types was observed. Additionally, DZIP3 regulated several cell cycle proteins by modulating the Cyclin D1–E2F axes. Taken together, this study demonstrates for the first time that DZIP3 uses a unique two-pronged mechanism in its stabilization of Cyclin D1 to drive cell-cycle and cancer progression. Significance: These findings show that DZIP3 is a novel driver of cell-cycle and cancer progression via its control of Cyclin D1 mRNA and protein stability in a cell-cycle phase-dependent manner.


  • IRGM links autoimmunity to autophagy

    by Parej Nath, Kautilya Kumar Jena, Subhash Mehto, Nishant Ranjan Chauhan, Rinku Sahu, Kollori Dhar, Kolapalli Srinivas, Swati Chauhan, Santosh Chauhan

    IRGM is a genetic risk factor for several autoimmune diseases. However, the mechanism of IRGM-mediated protection in autoimmunity remains undetermined. The abnormal activation of type I interferon (IFN) response is one of the significant factors in the pathogenesis of several autoimmune diseases. In our recent study, we showed that IRGM is a master suppressor of the interferon response. We found that the depletion of IRGM results in constitutively activated CGAS-STING1, DDX58/RIG-I-MAVS, and TLR3-TICAM1/TRIF signaling pathways resulting in upregulation of almost all IFN-responsive genes. Mechanistically, IRGM utilizes a two-pronged mechanism to suppress the interferon response. First, it mediates SQSTM1/p62-dependent selective macroautophagy/autophagy of nucleic acid sensor proteins, including CGAS, DDX58/RIG-I, and TLR3. Second, it facilitates the removal of defective mitochondria by mitophagy and avoids a buildup of mito-ROS and mito-damage/danger-associated molecular patterns (DAMPs). Thus, IRGM deficiency results in increased nucleic acid sensors and DAMPs engaging a vicious cycle of aberrant activation of IFN response that is known to occur in systemic autoimmune-like conditions.